Jobs
-
PPD is currently looking to recruit a Scientist to be based in our cGMP Lab in Athlone, Ireland. The basic purpose of the Scientist role is to perform a variety of complex sample preparation and… Read more . . .
-
GlaxoSmithKline has acquired rights to several inhaled drug candidates manufactured using Liquidia Technologies’ PRINT (Particle Replication In Non-Wetting Templates) platform. The PRINT nanofabrication technology produces particles with narrow size distribution and any desired shape. According… Read more . . .
-
Particle design and dry powder inhalation specialist Hovione has announced that sales for the fiscal year that ended in March, 2012 increased to $180 million,a 24% increase over the previous year. In addition to inhalation… Read more . . .
-
Liquidia Technologies is seeking a talented technical leader to join the company’s pharmaceutical research and development efforts. Job description • Hands-on technical leadership role designing and developing novel particle-based product candidates • Develop and execute… Read more . . .
-
Liquidia Technologies, Research Triangle Park, NC, is seeking a talented individual to join the pharmaceutical development team. This role will support research programs through development and scale-up of clinical and commercial formulations for pharmaceutical products… Read more . . .
-
MicroDose Therapeutx and Moerae Matrix have agreed to collaborate on development of a dry powder inhaler, using MicroDose DPI technology to deliver Moerae’s MMI-0100 MK2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). There… Read more . . .
-
According to Bloomberg News, Merck plans to appeal a ruling by Judge Peter Sheridan of the US District Court for the District of New Jersey that Merck failed to prove its allegation that Apotex infringed… Read more . . .
-
Rigel Pharmaceuticals has granted AstraZeneca an exclusive worldwide license for development and commercialization of its R256 inhaled JAK inhibitor for the treatment for moderate to severe asthma. The deal includes an upfront payment of $1… Read more . . .
-
A new report from Transparency Market Research titled “Asthma and COPD Drug Market – Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 – 2017” predicts an increase in the asthma and COPD… Read more . . .
-
Civitas Therapeutics has announced the initiation of a Phase 2a clinical trial of its CVT-301 inhaled L-dopa for the treatment of motor fluctuations in patients with Parkinson’s disease. CVT-301 is formulated and delivered using the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.